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ABSTRACT
Objective: The present report evaluates the protective effects of luteolin against diabetic retinopathy (DR).
Materials and methods: Diabetes was induced in rats by i.p. administration of 60 mg/kg of streptozotocin
(STZ), followed by treatment with luteolin for 4 weeks. The effects of luteolin were determined based on the
blood glucose and cytokine levels, and parameters of oxidative stress in retinal tissue of DR rats. The
diameter of retinal vessels was estimated by fundus photography. A Western blot assay was used to
determine the expression of apoptotic proteins and Nod-like receptor 3 (NLRP3) pathway proteins in the
retina of DR rats. A molecular docking study was performed to evaluate the interaction between luteolin
and NLRP3. Results: The level of blood glucose was reduced in the luteolin-treated group compared with
the DR group. Reductions in cytokines and oxidative stress were observed in the retinal tissues of the
luteolin-treated group relative to the DR group. Moreover, treatment with luteolin reduced the expression
of NLRP1, NOX4, TXNIP, and NLRP3 proteins, and ameliorated the altered expression of apoptotic
proteins in the retina of DR rats. Conclusion: In conclusion, luteolin prevents retinal apoptosis in DR rats
by regulating the NLRP/NOX4 signalling pathway.
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INTRODUCTION
Diabetes is a chronic metabolic disorder characterized by an increased glucose level that affects
approximately 170 million people worldwide [1]. Left uncontrolled for a long time, hyper-
glycaemia leads to several chronic complications including diabetic retinopathy (DR) [2]. DR is
a form of progressive retinal microvasculature damage and a major cause of loss of vision
worldwide [3]. Retinal damage in DR is classified into two primary types: proliferative and non-
proliferative [4]. Diabetic macular oedema occurs in retinal tissues in non-proliferative DR.
However, alterations in the growth and formation of blood vessels also occur under low-oxygen
conditions in the proliferative type [5]. Changes in vascular permeability cause injury to the
macula and an accumulation of fluids in retinal tissues, which are characteristic of DR [6].
Several pathways are involved in DR, as reactive oxygen species (ROS) formation is enhanced
due to alterations in the citric acid and glycolysis cycles as a result of hyperglycaemia. The activities
of ROS-generating enzymes, such as NADPH oxidase 4 (NOX4) are enhanced by inflammatory
processes promoted by an increase in cytokine level [7]. The literature suggests that the inflam-
mation involved in the development of DR, and retinal tissue necrosis and apoptosis is caused by
elevated caspase-1 expression [8]. Nod-like receptors (NLRP)-1 and -3 promote the expression of
IL-18 and IL-1b, which activate caspase-1 [9]. Collectively, this contributes to progressive damage
to the retinal tissue in DR. Current therapies available for DR have several limitations. Thus, there
is a clear need for the development of new drug targets and therapies for DR.
Several molecules of natural origin have shown potent effects against chronic disorders,
including diabetic complications. Luteolin is a flavonoid that acts as an antagonist of the aryl
hydrocarbon receptor isolated from Eclipta alba [10]. Previous reports have described geneti-
cally modified rats in which aryl hydrocarbon receptor deficiency enhanced insulin sensitivity,
and its antagonists protected against diabetes [11]. Luteolin reportedly has antidiabetic, anti-
inflammatory, anti-obesity, antioxidant, and neuroprotective effects [12, 13]. Moreover, luteolin
prevents vascular injury and protects against atherosclerosis by regulating the NLRP-3 pathway
[14]. The anti-inflammatory properties of luteolin are reflected in its ability to reduce levels of
IL-6 and NF-kBp65, and thereby exert anticancer effects [15]. The present report evaluates the
protective effect of luteolin against retinal injury in DR.
MATERIAL AND METHODS
Animals
Healthy (200–250-g) Wistar rats were maintained under controlled conditions as per guidelines
of Association for the Assessment and Accreditation of Laboratory Animal Care International
(AAALAC) for experimentation and animal use [16] (12-h light/dark cycle, 25 ± 3 8C, and 60 ±
5% humidity). All experimental protocols reported here were approved by the Institutional
Animal Ethics Committee of Affiliated Zhongshan Hospital of Dalian University, China.
Experimental
Animals of different groups were fasted overnight before the i.p. administration of 60 mg/kg of
streptozotocin (STZ) for the induction of diabetes. Diabetes was confirmed based on the serum
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level of glucose, determined using an autoanalyzer (Biobase Biodustry (Shandong) Co., Ltd.,
Shandong, China). The rats were randomly divided into three groups: the normal group, DR
group, and luteolin group. The luteolin group received luteolin 50 mg/kg p.o. for 4 weeks after
the induction of DR. At the end of the treatment period, the blood glucose level was determined
in all groups.
Fundus photography. Isoflurane was used to anesthetize the rats, and tropicamide was applied
to the eyes to dilate the pupils. The rats were placed beneath a retinal camera, and a clear image
of the retina was obtained. Image-Pro Plus software (Media Cybernetics, Silver Spring, MD,
USA) was used to determine the diameter of the blood vessels.
Measurement of oxidative stress. A riboflavin-sensitized method was used to assess the activity
of superoxide dismutase (SOD): 2 mL of reaction mixture containing 6.63 10 3 M EDTA, 102 M
methionine, 1.76 3 104 M nitroblue tetrazolium, 2 3105 M sodium cyanide (NaCN) and
2 3 106 M riboflavin in 50 mM phosphate buffer (pH 7.8) was added to each tube, followed by
5 mL sample. Tubes were placed for a period of 10 min under a 15 W lamp and the absorbance
was measured at 460 nm. Data of activity of SOD were expressed as U/mg protein [17].
The method reported by Ohkawa was used to determine the level of lipid peroxidation in
retinal tissues. Tissue homogenate (0.5 mL) was added to 1 mL of 0.67% thiobarbituric acid
(TBA) and 5 mL of 20% trichloroacetic acid (TCA) in aqueous solution. The mixture was heated
in a boiling water bath for 15 min and then cooled. The mixture was further treated with 4 mL of
n-butanol and then centrifuged for 15 min at 3,000 rpm. The malondialdehyde (MDA) level was
determined in retinal tissue at a wavelength of 530 nm in a spectrophotometer (Shimadzu
corporation, Japan) [18].
Measurement of cytokines. The levels of cytokines, namely NF-kB, IL-1b, IL-6, and TNF-a in
the eye tissue were determined using an ELISA kit (ThermoFisher Scientific, USA) according to
the manufacturer’s recommendations and evaluated by an ELISA reader (BioTek, Winooski,
Vermont, USA).
Western blotting. The expression levels of caspase-1, Bax, Bcl2, IL-1b, NLRP1, NOX4, TXNIP,
and NLRP3 were measured in isolated eye tissues using Western blotting. RIPA buffer con-
taining Phosphatase Inhibitor Cocktail and Halt Protease was used to homogenize the isolated
retinal tissue. The protein content in tissue homogenates was determined using the BCA assay
kit, and proteins were separated by 10% sodium dodecyl sulphate–polyacrylamide gel electro-
phoresis. The separated proteins were transferred to nitrocellulose membrane, which was then
blocked in 5% blocking reagent. The membrane was incubated with primary antibodies tar-
geting caspase-1, Bax, Bcl2, IL-1b, NLRP1, NOX4, TXNIP, and NLRP3 (ThermoFisher Scien-
tific, USA) overnight at 4 8C. After washing with PBS, the membrane was incubated with goat
secondary antibodies conjugated to horseradish peroxidase, and protein expression was detected
using a chemiluminescence kit. Chemiluminescence was detected with an Enhanced Chem-
iluminescence (ECL) Western blot detection kit (Amersham Pharmacia Biotech, Buck-
inghamshire, UK). To confirm that equal amounts of protein were electrophoresed and
transferred to the membrane, staining with Coomassie Brilliant Blue (CBB) R-250 was per-
formed.
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Estimation of caspase-1 activity. A caspase-1 colorimetric assay kit was used to determine the
caspase-1 activity in the retinal tissue, as per the manufacturer’s instructions (SigmaAldrich Ltd.,
USA). Data are presented as caspase-1 activity per unit weight of protein.
Histopathology study
Harvested rat eye tissues were fixed by seeding in 4% paraformaldehyde, and 4-mm-thick retinal
tissues were sectioned. Tissue sections were rehydrated with ethanol, and haematoxylin-eosin
staining was used to stain each section. Light microscopy was applied to observe pathological
changes in the eye tissue.
Homology model of NLRP3. The protein sequence of the NLRP3 protein was obtained from the
NCBI database for preparation of the homology model. The SWISS-MODEL server was used to
develop the homology model for the NLRP3 protein by SWISS modeling. Several software
packages were used to perform the investigation, including ACD ChemSketch (ACD Labs,
Ontario, Canada)), the PyMol Molecular Graphics System (version 2.4.0; Schrodinger, LLC,
New York, NY, USA), and Autodock Vina (ver. 1.5.6; (The Scripps Research Institute, La Jolla,
CA, USA). A universal protein source was used to sequence the NLRP3 protein. Target se-
quences against the primary amino acid sequence were identified via BLAST search. The best-
quality templates were selected for building the homology model. Autodock Vina was used to
prepare the ligand for the docking study.
Preparation of proteins and ligands, and molecular docking. The two-dimensional ligand
structure was obtained from the PubChem database and converted into a pdb file using Open
Babel software (http://openbabel.org/wiki/Main_Page). Autodock Vina was used to prepare li-
gands for the docking study by removing water molecules and adding hydrogen, and then
modulating the charges using the Kollman approach; finally, the pdbqt file was obtained. The
molecular docking simulation of luteolin was done using Autodock based on the Kollman and
Gasteiger charges in the ligand and protein. The grid map was created using AutoGrid 4 in
AutoDock Vina. After preparing the grid box, the area of the protein structure to be mapped was
defined. The grid box dimensions (x, y, and z coordinates) for NLRP3 were 79.658853,
99.032284, and 93.160451, respectively. A Lamarckian genetic algorithm was used for mini-
mization and optimization of energies in the docking simulation process.
Statistical analysis
All data are expressed as mean ± standard error of the mean (SEM; n5 10), and statistical analysis
was performed using one-way analysis of variance (ANOVA). Post hoc comparisons of means were
carried out with Dunnett’s test using GraphPad Prism software (ver. 6.1; GraphPad Software, Inc.,
San Diego, CA, USA). Data with P value <0.05 were considered statistically significant.
RESULTS
Luteolin reduces the blood glucose level
The serum glucose level of luteolin-treated DR rats was estimated on days 3 and 8, as shown in
Fig. 1. An increase in the serum glucose level of the DR and luteolin groups compared with the
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normal group was observed after 3 days of STZ administration. The serum glucose level was
further enhanced in the DR group compared with the normal group. However, treatment with
luteolin reduced the concentration of glucose in the serum of DR rats.
Luteolin reduces the diameter of retinal vessels
The effect of luteolin on the diameter of retinal vessels in the DR rats is shown in Fig. 2. On
fundus photography, the retinal arteriolar diameter was 74.9 mm in the DR group and 38.6 mm
in the normal group. In the luteolin-treated group, the retinal arteriolar diameter was decreased
to 46.1 mm compared with the DR group.
Luteolin reduces oxidative stress
Parameters of oxidative stress, such as MDA level and SOD activity were estimated in the retinal
tissue of luteolin-treated DR rats. The MDA level in wet tissue was 10.4 mM/mg higher, whereas
the SOD level in wet tissue was 0.73 U/mg lower in the tissue homogenate of the DR group
compared with the normal group. However, treatment with luteolin reduced the magnitude of
the change in MDA level and SOD activity in the retinal homogenate of DR rats (Fig. 3).
Luteolin reduces the level of cytokines
Cytokine levels in the retinal tissues of luteolin-treated DR rats were determined, as shown in
Fig. 4A and B. ELISA was used to estimate the IL-1b, IL-6, TNF-a, and NF-kB levels in the
retinal tissues of luteolin-treated DR rats. There was an increase in cytokine concentrations in
the tissue homogenate of the DR group relative to the normal group. The cytokine concen-
trations were reduced in the luteolin-treated group compared with the DR group (Fig. 4A). IL-
1b expression in the tissue homogenate of the DR group was enhanced compared with that in
the normal group. Finally, the expression of IL-1b in the retinal tissues of the luteolin-treated
group was lower than that in the DR group (Fig. 4B).
Fig. 1. Luteolin treatment reduces the serum glucose level in DR rats.
Mean ± SEM (n 5 10); ##P < 0.01 compared with the normal group; ppP < 0.01 compared with the
DR group
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Luteolin reduces retinal apoptosis
Retinal cell apoptosis was determined by estimating the expression levels of the caspase-1, Bax,
and Bcl-2 proteins, and the activity of caspase-1 in the retina of luteolin-treated DR rats (Fig. 5A
and B). Caspase-1, Bax, and Bcl-2 protein expression levels were estimated using a Western blot
assay, as shown in Fig. 5A. The expression levels of caspase-1 and Bax were increased, whereas
Fig. 3. Luteolin reduces oxidative stress in retinal tissues in DR rats.
Mean ± SEM (n 5 10); ##P < 0.01 compared with the normal group; ppP < 0.01 compared with the
DR group
Fig. 2. Effect of luteolin on fundus photography and the diameter of retinal vessels in DR rats.
Mean ± SEM (n 5 10); ##P < 0.01 compared with the normal group; ppP < 0.01 compared with the
DR group
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that of Bcl-2 protein was decreased in the tissue homogenate of the DR group relative to the
normal group. However, treatment with luteolin attenuated the altered expression of Bax, cas-
pase-1, and Bcl-2 proteins in DR rats. The activity of the caspase-1 enzyme was also estimated in
the tissue homogenate of DR rats, as shown in Fig. 5B. The activity of caspase-1 was enhanced in
the retina in the DR group compared with the normal group. The activity of caspase-1 enzyme in
the retina in the luteolin-treated group was reduced compared with the DR group.
Luteolin facilitates NLRP1/NOX4 pathway activation
Luteolin affected the expression of the NLRP1, NOX4, TXNIP, and NLRP3 proteins in the
retinal tissue of DR rats. The expression of the NLRP1, NOX4, TXNIP, and NLRP3 proteins in
the retinal tissue homogenate of the DR group was significantly enhanced compared with the
normal group. Expression levels of the NLRP1, NOX4, TXNIP, and NLRP3 proteins were
reduced significantly (P < 0.01) in the retinas of luteolin-treated rats compared with DR rats
(Fig. 6).
Luteolin ameliorates pathological changes in retinal tissue
Histopathological changes in the retina in luteolin-treated DR rats were observed by H&E
staining. In the DR group, histopathology of the retina suggested oedema, congestion, and
vascular structure enhancement, as well as a loss of ganglion cells. However, treatment with
luteolin reversed the histopathological changes in the retina in DR rats (Fig. 7).
Effect of luteolin on the NLRP3 protein
Luteolin had high binding affinity with the NLRP3 protein. An in vivo and in vitro molecular
docking study was performed using BLAST and homology modeling, followed by ligand and
Fig. 4. Luteolin reduces inflammatory cytokines in retinal tissues in DR rats. A: Concentrations of the
cytokines IL-1b, IL-6, TNF-a, and NF-kB in the retinal tissues, as revealed by ELISA; B: Relative expression
of IL-1b, as revealed by Western blot assay.
Mean ± SEM (n 5 10); ##P < 0.01 compared with the normal group; ppP < 0.01 compared with the
DR group
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Fig. 6. Luteolin reduces the expression of NLRP1, NOX4, TXNIP, and NLRP3 in retinal tissues in DR rats.
Mean ± SEM (n 5 10); ##P < 0.01 compared with the normal group; ppP < 0.01 compared with the
DR group
Fig. 5. Luteolin reduces apoptosis in the retinal tissues of DR rats. A: Relative expression of Bax, Bcl-2, and
Caspase-1 in retinal tissues, as revealed by Western blot assay; B: Activity of caspase-1, as revealed by
caspase-1 assay.
Mean ± SEM (n 5 10); ##P < 0.01 compared with the normal group; ppP < 0.01 compared with the
DR group
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protein preparation. A luteolin molecular docking simulation was done using Autodock based
on the Kollman and Gasteiger charges in both the ligand and the protein. The results showed
higher binding affinity for luteolin with both in vivo-confirmed proteins and the NLRP3 protein.
The binding energy data showed that luteolin was bound to NLRP3 (Table 1). Three-dimen-
sional and two-dimensional structural analysis of the protein revealed a solid area, representing
the binding area between the ligand and the NLRP3 protein (Fig. 8A and B).
Fig. 7. Luteolin reduces histopathological changes in retinal tissues in DR rats
Table 1. Docking scores for NLRP3 protein with ligand molecule Luteolin
Mode of ligand Affinity (kcal/mol) Distance from rmsd l.b Best mode rmsd u.b
1 8.2 0.000 0.000
2 8.1 3.403 5.091
3 7.9 3.350 7.416
4 7.8 3.484 5.896
5 7.7 1.169 2.689
6 7.6 1.737 6.978
7 7.4 19.137 19.502
8 7.1 1.458 6.771
9 7.0 3.122 4.491
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DISCUSSION
Diabetic retinopathy is a major complication of diabetes, contributing to the loss of vision.
Management of diabetic retinopathy is still a challenge, and novel therapies are needed.
Therefore, the present report evaluated the protective effect of luteolin against diabetic reti-
nopathy (specifically, its effect on blood glucose and cytokine levels), as well as parameters of
oxidative stress in the retinal tissue of diabetic retinopathy rats.
Alterations in the retinal microvascular circulation lead to changes in the retinal structure in
diabetes mellitus [19]. In diabetic retinopathy, changes in vascularization, oedema, hyper-
proliferation of endothelial cells, and increased vascular permeability result in the loss of vision.
The literature indicates that luteolin regulates blood glucose in diabetic rats [11], and the data of
Fig. 8. In silico molecular docking showing the interaction of NLRP3 protein with luteolin. The solid area
in the protein structures represents the area of interaction with the ligand. A: Three-dimensional molecular
structure; B: Two-dimensional molecular structure
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the present study also suggest that treatment with luteolin reduces the serum glucose concen-
tration in diabetic retinopathy rats.
Diabetic retinopathy changes the flow of blood to the retina, resulting in an increase in ROS
production, which in turn enhances oxidative stress [20]. Oxidative stress and ROS production
are increased by overexpression of NOX4, and in a previous report the expression of NOX4 was
found to be enhanced in diabetic retinopathy [21]. The results of the present study support this
finding. Moreover, hyperglycaemia enhances the expression of the thioredoxin-interacting
protein (TxNIP), and a recent study reported that b-cell failure was not seen in TxNIP-deficient
mice [22]. This finding suggested that expression of the TXNIP protein was enhanced in the
diabetic retinopathy group compared with the normal group. The expression of TXNIP and
NOX4 was reduced, as was oxidative stress, in the retinas of the luteolin-treated group compared
with the diabetic retinopathy rats.
Oxidative stress increases due to changes in the expression of cytokines, such as IL-1b and
IL-18, which are activated by higher levels of NLRP-1 and -3 [23]. NLRP-1 and -3 enhance the
activity of the caspase-1 enzyme and alter apoptotic protein expression patterns. Previous
studies indicated that activation of NLRP-1 or -3 was involved in the pathogenesis of diabetic
retinopathy [24]; the data of the present study support this conclusion. Our results indicate that
treatment with luteolin reduces the increase in cytokine levels and the expression of NLRP-1 and
-3 in the retinal tissue of diabetic retinopathy rats. Alterations in the expression of NLRP 1 and
interleukins activate apoptosis in the retina [25]. Moreover, our data show that retinal apoptosis
contributes to the loss of vision, such that diabetic retinopathy is a major cause of blindness. The
expression of apoptotic proteins and the activity of caspase-1 showed greater reductions in the
luteolin-treated group than in the diabetic retinopathy group. Moreover, the histopathological
study revealed that treatment with luteolin attenuates the pathological changes that occur in the
retina in diabetic retinopathy rats. Our report presented here has a few limitations, such as the
study didn't evaluate the effect of luteolin clinically. Moreover, the dosage form for the
administration of luteolin also needs to be developed, and the pharmacokinetic data of luteolin
need to be studied.
CONCLUSION
In conclusion, a diabetic retinopathy rat model has been successfully established in this report,
which will contribute to the therapeutic development of drugs for diabetic retinopathy. The
present report also establishes the evidence of contribution of the NLRP/NOX pathway in the
development of retinal injury in diabetic retinopathy, and demonstrates that treatment with
luteolin ameliorates retinal apoptosis in diabetic retinopathy rats by regulating the NLRP1/
NLRP3/ NOX4 signalling pathway. Thus, luteolin could be used clinically for the management
of diabetic retinopathy.
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